Long-term changes in body weight and serum cholesterol in heart transplant recipients

Kyoko Miura1,2, Regina Yu1, Timothy R Entwistle3

  • 1Population Health Department, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.

Clinical Transplantation
|September 8, 2022
PubMed

Insights

Heart transplant recipients gain significant weight and experience elevated blood lipids within 36 months post-transplant. Statin therapy influences cholesterol levels, highlighting the need for ongoing management in heart transplant patients.

Area of Science:

  • Cardiology
  • Transplantation Medicine
  • Metabolic Health

Background:

  • Long-term outcomes of weight and blood lipid changes after heart transplantation are not well-documented.
  • Understanding these changes is crucial for managing post-transplant patient health.

Purpose of the Study:

  • To quantify changes in weight, BMI, cholesterol, and triglycerides up to 36 months post-heart transplantation.
  • To evaluate the impact of statin therapy on these metabolic parameters.

Main Methods:

  • Retrospective cohort study of adult heart transplant recipients (HTRs) in Australia.
  • Data extracted from medical charts at baseline, 12, 24, and 36 months post-transplant.
  • Analysis of weight and blood lipid changes based on baseline BMI and statin use.

Main Results:

  • All included HTRs experienced significant weight gain over 36 months, particularly those with lower baseline BMI.
  • Mean blood cholesterol and triglycerides also increased significantly in all patients.
  • Total cholesterol levels were higher in non-statin users and varied with statin dosing changes.

Conclusions:

  • Heart transplant recipients show significant increases in weight and blood lipids within the first 36 months.
  • These findings underscore the importance of monitoring metabolic changes and optimizing statin therapy in HTRs.
Abstract

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
50
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
271
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
77
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
25
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
195